Rubius Therapeutics Debt to Equity

Rubius Therapeutics posts a debt-to-equity ratio of 0.15. That is above the Healthcare sector average of -8.48. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a debt-to-equity ratio near -8.48 is typical. Rubius Therapeutics's 0.15 is higher that level. That is roughly 101.7% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Rubius Therapeutics's debt-to-equity ratio of 0.15 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for RUBY's debt-to-equity ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -8.48), and (3) consistency with growth and profitability. This page covers the first two; Rubius Therapeutics's other metric pages and overview cover the third.

Judging Rubius Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in debt-to-equity ratio easier to interpret. Start with 0.15 here, then scan peer and history charts to see if the gap is persistent.